Table 1: Phase III randomized, controlled trials investigating switch maintenance therapy.

 

Trial

Induction chemotherapy

Maintenance regimen

Median PFS

Median OS

GCOT, Westeel et al. JNCI 2005 [10]

Mitomycin + ifosfamide + cisplatin (MIC) 4 cycles (or 2 cycles + radiation if stage IIIB)

Vinorelbine 6 months vs.

no further treatment

5 vs. 3 months,

p = 0.11

12.3 vs. 12.3 months, p = 0.65

Sculier et al.

Ann Oncol 2007 [11]

Gemcitabine + ifosfamide + cisplatin (GIP) 3 cycles

Paclitaxel vs. GIP

4.0 vs. 4.4 months,

p = 0.56

9.7 vs. 11.9 months,

p = 0.17

JMEN, Ciuleanu et al.

Lancet 2009 [12]

Platinum-based chemo 4 cycles

Pemetrexed vs. placebo

4.3 vs. 2.6 months,

P < 0.0001

13.4 vs. 10.6 months, p = 0.012

Fidias et al. JCO 2009 [13]

Carboplatin + gemcitabine 4 cycles

Immediate vs. delayed docetaxel maximum 6 cycles

5.7 vs. 2.7 months,

p = 0.0001

12.3 vs. 9.7 months,

p = 0.0853

SATURN, Cappuzzo et al. Lancet Oncol 2010 [14]

Platinum-based chemo 4 cycles

Erlotinib vs. placebo

12.3 vs. 11.1 weeks,

p < 0.0001

12.0 vs. 11.0 months, p = 0.0088

Perol et al. JCO 2012 [16]

Cisplatin + gemcitabine 4 cycles

Erlotinibvs. observation (vs. gemcitabine)

2.9 vs. 1.9 months,

p = 0.003

11.4 vs. 10.8 months, p = 0.3043

ATLAS, Johnson et al.

JCO 2013 [15]

Chemotherapy + bevacizumab 4 cycles

Bevacizumab + erlotinib vs. bevacizumab + placebo

4.8 vs. 3.7 months,

p < 0.001

14.4 vs. 13.3 months, p = 0.5341